Key result
Cardiac biomarkers, including troponin, natriuretic peptides, and novel markers like sST2, play a crucial role in the early detection and monitoring of cancer treatment-induced cardiotoxicity.
Why the study?
Cardiological complications of oncological treatment are a significant, potentially life-threatening problem, making early detection via biomarkers crucial to prevent adverse cardiovascular outcomes.
Cardiac biomarkers play a crucial role in the early detection of cancer therapy-induced cardiotoxicity, allowing for timely implementation of cardioprotective strategies.
Cancer and cardiovascular diseases are a leading causes of morbidity and mortality in developed countries. Cardiological complications of oncological treatment are a significant problem that can be manifested in both permanent and transient cardiac dysfunction including myocardial damage, left ventricular dysfunction, and heart failure, hypertension, ischemia, as well as arrhythmias or QT prolongation, which can be life-threatening. Early detection of cardiotoxicity due to cancer treatment is crucial in the prevention of adverse cardiovascular outcomes in this group of patients. In this review we try to summarize the role of biomarkers in the detection of cardiotoxicity due to cancer treatment.
No takes yet. Share an insight, caveat, or question.
Dudek et al. (2020) conducted a review in Cancer treatment-induced cardiotoxicity. Cardiac biomarkers (troponin, natriuretic peptides, sST2, MPO) was evaluated. Cardiac biomarkers, including troponin, natriuretic peptides, and novel markers like sST2, play a crucial role in the early detection and monitoring of cancer treatment-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: